Podcasts about marginal zone lymphoma

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Following the 2024 Marginal Zone Lymphoma (MZL) Workshop, CancerNetwork® spoke with multiple attending clinicians about insights they shared regarding the disease state, covering the significance of the workshop and its contribution to advancing research in areas such as prognostic factors and managing adverse events (AEs) related to the disease. Thomas Habermann, MD, professor of Medicine at the Mayo Clinic in Rochester, Minnesota, member of the Lymphoma Research Foundation's Scientific Advisory Board, and MZL Workshop co-chair, spoke about the significance of the MZL Workshop. He highlighted the complexity of these types of diseases, which he believed warranted the establishment of the group. According to Habermann, MZL is a “heterogenous group of disorders” that most contemporaries in the field “don't quite appreciate.” Next, Julie M. Vose, MD, MBA, George and Peggy Payne chair in oncology and chief of Hematology and Oncology at the University of Nebraska Medical Center, and co-editor-in-chief of ONCOLOGY®, spoke about how the MZL Workshop contributes to advancing research and improving outcomes for patients with MZL. She emphasized a need to be more inclusive when enrolling patients with MZL in clinical trials. Then, James R. Cerhan, MD, PhD, professor of Epidemiology at the Mayo Clinic College of Medicine and Science, and Ralph S. and Beverly Caulkins Professor of Cancer Research, spoke about addressing research questions in MZL epidemiology to further disease understanding. He emphasized a need to further study newly identified risk factors of the disease, as well as identifying new treatment targets for patients with MZL. Additionally, Alexandar Tzankov, MD, surgical pathologist and head of the Department of Histopathology and Autopsy at the Institute of Medical Genetics and Pathology at University Hospital Basel, and chair for the European Bone Marrow Working Group, discussed how prognostic factors for MZL may influence treatment. He described how the limited number of studies done with relatively small subsets of patients makes prognoses challenging, as prognostic factors have not been sufficiently explored. Finally, Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, outlined challenges related to AE management of treatments for MZL. He emphasized that safety management practices for MZL are comparable with other B-cell lymphomas, suggesting that use of bridging therapy for CAR T cells and step-up dosing for bispecific antibodies may help with mitigating AEs.

This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now! Click here to claim you free CME/NCPD credit: https://bit.ly/3OFBxiX

This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!

Juan Pablo Alderuccio, MD, assistant professor of medicine in the Division of Hematology, Department of Medicine at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine in Florida, spoke with CancerNetwork® about his review published in the journal ONCOLOGY® titled, Current Treatments in Marginal Zone Lymphoma. In the article, Alderuccio explored current approaches to the diagnosis and treatment of marginal zone lymphoma. He also touched on his strategies for treating localized versus advanced disease and novel emerging strategies clinicians practicing in the community should be aware of.   Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Was the Omicron variant more deadly than Delta? Find out this and more in today's PV Roundup podcast.

Was the Omicron variant more deadly than Delta? Find out this and more in today's PV Roundup podcast.

In this episode, Julie M. Vose, MD, MBA;  Brad S. Kahl, MD; and  John P. Leonard, MD, discuss treatment approaches for patients with B-cell lymphomas, including information on: Follicular lymphomaMarginal zone lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaPosttransplant lymphoproliferative disorderPresenters:Julie M. Vose, MD, MBAChief, Division of Oncology and HematologyNeumann M. and Mildred E. Harris ProfessorDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaBrad S. Kahl, MDProfessor of MedicineDepartment of Medical OncologyWashington University School of MedicineSt Louis, MissouriJohn P. Leonard, MDRichard T. Silver Distinguished Professor of Hematology and Medical OncologyProfessor of MedicineWeill Cornell MedicineNew York Presbyterian HospitalNew York, New YorkLink to the complete program, including downloadable slidesets, expert commentaries, an on-demand webcast, and treatment resource guides:https://bit.ly/3tb47wU

What are the long-term cardiovascular outcomes of COVID-19? Find out about this and more in today's PV Roundup podcast.

Experts discuss the role of PI3K inhibitors in R/R follicular and marginal zone lymphoma. Credit available for this activity expires: 11/2/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/961885?src=mkm_podcast_addon_961885

Listen to a soundcast of the September 14, and 15, 2021, FDA approvals of Brukinsa (zanubrutinib), for relapsed or refractory marginal zone lymphoma, and Exkivity (mobocertinib) for adult patients with locally advanced or metastatic non-small lung cancer.

Owen A. O'Connor, Chief Scientific Officer at TG Therapeutics, gives an overview of follicular lymphoma (FL) and marginal zone lymphoma (MZL).

Owen A. O'Connor, Chief Scientific Officer at TG Therapeutics, discusses umbralisib, which was approved for the treatment of relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)